Pediatric Health Dispatch, August 4, 2026

This edition is brought to you by [Sponsor Name]
[75 to 100 word native sponsor paragraph. Placeholder, no sponsor confirmed for this edition.]

Wildflower Health acquires Every Mother, terms undisclosed.

Wildflower is a payer- and provider-contracted maternity navigation company supporting roughly 100,000 women between appointments. It just bought Every Mother, a virtual core and pelvic floor therapy platform sold direct to consumers on an HSA/FSA basis, in what it calls its first move into D2C care. The direction of travel is the story: enterprise buying consumer, which is the inverse of the usual femtech pattern where a D2C brand tries to earn its way into enterprise contracts. Pelvic floor rehabilitation is exactly the kind of postpartum service the global maternity fee absorbed and never priced separately, and Wildflower is assembling postpartum service lines roughly twelve months before postpartum care may become independently codeable. Reading the policy calendar is a better explanation than luck.

Pediatrica Health Group, $28M Series B.

Valspring Capital led, with existing investor M33 Growth participating, in a round that funds acquisitions, clinical infrastructure, and value-based care capability across Pediatrica's 21 pediatric primary care locations in Florida and Texas. This is the largest disclosed pediatric primary-care round since Zarminali's $110M Series A in January and the clearest sign yet that institutional growth capital will underwrite brick-and-mortar pediatrics again, not just software. Valspring is a healthcare specialist firm founded by Bain Capital Ventures' former healthcare team, which matters more than the dollar figure: this is a category bet, not a generalist tourist. The execution question is payer mix. Florida and Texas are both Medicaid-heavy states with volatile Medicaid politics and stalled KidCare expansion, which is precisely where pediatric value-based care either pencils out or quietly does not.

Handspring Health, $19M Series B.

RPS Ventures led, with Angelini Ventures joining and Cobalt Ventures, NextView, nvp capital, Hyde Park Angels, and Cornucopian Capital returning. Handspring delivers virtual therapy, parent support, and medication management for children, teens, and young adults, and says it has served more than 4,000 families. The tell in this round is not clinical demand, which nobody disputes; it is that Handspring is in network with major commercial insurers and not with Medicaid. Pediatric behavioral health has become the most reliably fundable lane in the sector, and it is being funded almost entirely on the commercial book.

InStride Health, $30M Series C.

Echo Health Ventures and FMZ Ventures led, with .406 Ventures, Valtruis, General Catalyst, and Mass General Brigham Ventures returning, taking InStride to roughly $86M raised. The company treats complex pediatric anxiety and OCD for ages 7 to 24 across 17 states, pairing every patient with a psychiatrist, therapist, and exposure coach, and it bills insurance rather than families. Echo is a payer-affiliated strategic with Cambia and Mosaic lineage, which makes this round the second data point in a fortnight for the same thesis: capital is moving toward condition-specific pediatric behavioral specialty with a contracted payer channel, and away from generalist teletherapy.

NeuroBell, $5.5M Series A.

Elkstone led the US launch round for the Cork-based University College Cork spinout behind LUNA, an eight-channel neonatal EEG amplifier designed so ordinary NICU staff can run continuous brain monitoring without a neurophysiologist on hand. Most neonatal seizures produce no visible signs, so the clinical gap is real. The name that matters in the round is Parkview Health, a 15-hospital US system taking equity in a company whose FDA clearance is still pending. NICU startups sell devices into capital budgets rather than reimbursable services, the go-to-market problem our May NICU deep dive raised across the whole category, so a named health system anchor is worth considerably more here than the round size implies. Compare CergenX, chasing the same neonatal brain-monitoring bottleneck with FDA breakthrough designation but no disclosed US health system investor.

ONTO Health acquires LEVY Health, terms undisclosed.

ONTO, which raised a $20M Series A in April, is buying LEVY Health's reproductive-medicine software stack: clinical decision support, patient intake, lab ordering, and diagnostic workflow. Fertility has spent a decade competing on access, navigation, and conversion, which is how Kindbody and Progyny built their positions. ONTO is buying the diagnostic and workflow layer underneath that competition instead, a bet that owning time-to-treatment beats owning another clinic.

Woddle, $5M Seed.

Capital Q Ventures led this round for an AI-enabled infant monitoring platform, and the reason it earns a line is the framing: Woddle pitches NICU discharge, infant remote patient monitoring, payer reimbursement, and health-system deployment rather than a consumer nursery gadget. That puts it closer to Sibel and PyrAmes than to the baby-tech shelf. The caveat is not decorative: essentially every available detail is company- or investor-supplied, so treat the traction and reimbursement claims as unverified until a customer says so independently.

CMS built an escape hatch into maternity unbundling, and ACOG is fighting it in public.

CMS issued the CY2027 Physician Fee Schedule proposed rule on July 14. It recognizes the new AMA/ACOG obstetric CPT codes that split maternity billing into antepartum, labor management, delivery, and postpartum, and it raises proposed values for labor and delivery. It also proposes 15 new HCPCS G-codes that replicate the old bundled global maternity payment, so any payer uncomfortable with unbundling can simply keep billing the way it always has. Both code sets would take effect January 1, 2027. ACOG President Camille A. Clare objected on July 16 and urged CMS to "make a clean break," and she is right that running two billing structures at once raises administrative cost, undercuts the price transparency the new codes were built to create, and sorts patients into two tiers based on what their insurer chose. For vendors, the G-codes convert a market-wide reset into a payer-by-payer, state-by-state grind, which advantages companies already contracting one payer at a time (Wildflower, Maven, Pomelo Care) over anyone selling a single national product story. Comments close September 14. That is now the most consequential date on the maternal health calendar, and it falls while OBBBA directed-payment caps are already closing the maternity units these companies sell into.

ACOG told ob-gyns to build doulas into the care team. That is a credentialing event, not a payment event.

The committee statement "Partnering With Doulas in Clinical Settings" landed July 16 and runs in the August issue of Obstetrics & Gynecology. It sets five recommendations for ob-gyns, including building teams that include doulas and understanding local coverage pathways, and it grounds them in outcomes: shorter labor, fewer cesarean deliveries, higher breastfeeding initiation, with the largest benefit for patients the system has historically failed. The commercial consequence is that hospital labor and delivery units now have a professional-society recommendation to point at, which lowers the internal cost of justifying doula-inclusive programs and strengthens the case for doula credentialing, scheduling, and billing infrastructure as a product category rather than a nice-to-have. What a standards body cannot do is set a rate. Worth noting that ACOG spent the same stretch of July fighting CMS over the maternity G-codes and co-signing a $20B congressional ask on women's health, which is a professional society running out of patience on three fronts at once.

Arkansas got its doula payment machinery approved six days after becoming the cautionary tale.

On July 21 the Arkansas Center for Health Improvement reported the state was still finalizing reimbursement rules more than a year after Acts 124 and 965 mandated doula coverage. On July 22, CMS approved SPA AR-26-0004, adding Medicaid coverage for doula services alongside breastfeeding and lactation consultant services, retroactive to March 1. The pairing is the commercially interesting part: most doula SPAs cover labor support alone, and bundling lactation with it widens the postpartum stack a maternal platform can actually plug into. Arkansas has moved from authorized-but-not-live to live. What comes next is rates, provider enrollment, and whether a workforce can be built on them, which is where this benefit repeatedly gets stuck. Montana halted its rollout entirely over a $146M federal shortfall before reversing weeks later, and our May deep dive identified rate adequacy rather than coverage as the binding constraint: 27 states plus DC now cover doula services, and in nearly all of them the open question is whether the rate sustains a workforce.

MassHealth put real payment architecture behind higher-acuity pediatric behavioral care.

CMS approved Massachusetts SPA MA-25-0023 on July 24, updating payment methods for the Children's Behavioral Health Initiative and formally adding Family-based Intensive Treatment, an in-home service delivered through Community Service Agencies for members age 20 and younger. Massachusetts operates one of the oldest and most structured Medicaid pediatric behavioral infrastructures in the country, so when it changes payment methods it moves referral volume, provider economics, and the competitive line between venture-backed platforms and public-program-native providers. Read it against this week's Deal Watch and the contrast is instructive: capital is funding commercially contracted virtual specialty care (Handspring, InStride) while the state with the deepest public infrastructure is reinforcing family-based intensive treatment further up the acuity ladder. Those are two different markets, and the sickest Medicaid children are in the second one.

Casgevy reached two-year-olds, and the label wave keeps grinding down the age curve.

On July 1 the FDA approved Vertex's Casgevy (exagamglogene autotemcel) for sickle cell disease and transfusion-dependent beta thalassemia in patients ages 2 and older, down from 12, making it the first gene therapy cleared for children that young with sickle cell. Volume will stay small for years, but the operational burden will not: earlier eligibility means longer care arcs, more family coordination, and more load on referral management, prior authorization, and post-treatment monitoring at children's hospitals and the payers behind them. This is the identical pattern we tracked with Zoryve and Tzield. The FDA keeps approving downward into younger cohorts on its own schedule, and the machinery that would get an under-resourced family to those therapies keeps not getting built.

That's your Tuesday roundup. Thursday's deep dive: The Great Maternity Unbundling. Maternity billing is being re-architected for January 1, 2027, and CMS just proposed making it optional. We walk the mechanics (what the new CPT structure actually splits apart, what CMS proposed for the antepartum and postpartum component rates, and which state Medicaid agencies are committing to the CPT path), then name which companies finally get billable homes for the services the global fee absorbed, and which ones are about to learn their revenue was riding on a bundle that no longer exists.

Was this forwarded to you? Subscribe at pedshealthdispatch.com